Ralph Niven - Dec 14, 2021 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
Chief Development Officer
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Dec 14, 2021
Transactions value $
$0
Form type
4
Date filed
12/16/2021, 05:00 PM
Previous filing
Jun 29, 2021
Next filing
Aug 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +65.4K $0.00 65.4K Dec 14, 2021 Common Stock 65.4K $10.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022.